Nektar Therapeutics' experimental alopecia areata drug, rezpegaldesleukin, has demonstrated a "deepening" treatment response in patients who previously showed substantial hair regrowth. The new data comes from an extension study of the company's clinical trial, extending a comeback bid that has already caused the firm's shares to skyrocket over the past year.
Patients who had achieved significant hair regrowth during the initial phase of the trial showed continued improvement in the extension period. The treatment response deepened, suggesting the therapy's benefits may strengthen over time rather than plateau.